Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the C-terminus.
This protein contains a furin convertase cleavage site, 737-RKRR-740, and will be partially processed into N (α chain) and C-terminal fragment (partial β chain) with calculated MW of 81.1 kDa and 23.8 kDa respectively. The protein migrates as 45-50 kDa (partial β chain), 96-115 kDa (α chain) and 120 kDa (α chain & partial β chain) under reducing (R) condition (SDS-PAGE) due to glycosylation.
>90% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Cynomolgus IGF-I R, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
The purity of Cynomolgus IGF-I R, His Tag (Cat. No. IGR-C5225) is more than 85% and the molecular weight of this protein is around 255-311 kDa verified by SEC-MALS.
Immobilized Cynomolgus IGF-I R, His Tag (Cat. No. IGR-C5225) at 5 μg/mL (100 μL/well) can bind Human IGF-I, Fc Tag with a linear range of 5-78 ng/mL (QC tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Mecasermin (Astellas/OrphanPacific) | Approved | Astellas Pharma Inc | Somazon | Japan | Growth hormone deficiency; Diabetes Mellitus, Lipoatrophic; Dwarfism | null | 1994-10-05 | Diabetes Mellitus, Lipoatrophic; Heart Failure; Myocardial Infarction; Multiple Sclerosis; HIV-Associated Lipodystrophy Syndrome; Dwarfism; Growth hormone deficiency | Details | |
Mecasermin (Ipsen) | FK-780; IGF-1; MKN-031; rhIGF-I (Ipsen) | Approved | Genentech Inc | Increlex | United States | Failure to Thrive | Ipsen Inc | 2005-08-30 | Failure to Thrive; Autism Spectrum Disorder; Phelan-McDermid syndrome; X-Linked Combined Immunodeficiency Diseases; Growth Disorders; Laron Syndrome | Details |
Brigatinib | AP-26113 | Approved | Ariad Pharmaceuticals Inc | Alunbrig, ALUNBRIG | United States | Carcinoma, Non-Small-Cell Lung | Takeda Pharmaceuticals USA Inc | 2017-04-28 | Solid tumours; Ependymoma; Carcinoma; Neoplasms; Neurofibromatosis 2; Myofibroma; Lymphoma, Large-Cell, Anaplastic; Granuloma, Plasma Cell; Lung Neoplasms; Brain metastases; Carcinoma, Non-Small-Cell Lung; Sarcoma, Kaposi; Neurilemmoma; Neuroma, Acoustic; Meningioma | Details |
IGF-1 (Biogen/Pharmacia & Upjohn) | Approved | Biogen Inc, Pharmacia & Upjohn | Igef | Sweden | Dwarfism | null | 1994-01-01 | Dwarfism | Details | |
Ceritinib | LDK-378; NVP-LDK378; NVP-LDK378-NX | Approved | Novartis Pharma Ag | 赞可达, Zykadia | EU | Carcinoma, Non-Small-Cell Lung | Novartis Europharm Ltd | 2014-04-29 | Hepatic Insufficiency; Adenocarcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung; Brain metastases; Esophageal adenocarcinoma; Granuloma, Plasma Cell; Lymphoma, Large-Cell, Anaplastic; Thyroid Neoplasms; Hematologic Neoplasms; Colorectal Neoplasms; Cholangiocarcinoma; Neoplasms; Pancreatic Neoplasms; Glioblastoma; Thyroid Carcinoma, Anaplastic; Stomach Neoplasms | Details |
Teprotumumab | R-1507; RG-1507; RO-4858696; HZN-001; RV-001(River Vision) | Approved | Genmab A/S, F. Hoffmann-La Roche Ltd | Tepezza | United States | Graves Ophthalmopathy | Horizon Therapeutics Ireland | 2020-01-21 | Neoplasms; Graves Ophthalmopathy; Breast Neoplasms; Sarcoma; Diabetic macular oedema; Scleroderma, Diffuse; Carcinoma, Non-Small-Cell Lung | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Veligrotug | ZB-001; VRDN-001; AVE-1642 | Phase 3 Clinical | Viridian Therapeutics Inc | Solid tumours; Graves Ophthalmopathy; Multiple Myeloma; Breast Neoplasms | Details |
VRDN-003 | VRDN-003 | Phase 3 Clinical | Viridian Therapeutics Inc | Graves Ophthalmopathy | Details |
Ganitumab | AMG-479 | Phase 3 Clinical | Amgen Inc | Breast Neoplasms; Neuroectodermal Tumors, Primitive, Peripheral; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Lymphoma; Lung Neoplasms; Rhabdomyosarcoma, Alveolar; Colorectal Neoplasms; Neuroectodermal Tumors, Primitive; Sarcoma; Prostatic Neoplasms; Solid tumours; Sarcoma, Ewing; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Carcinoid Tumor; Rhabdomyosarcoma, Embryonal; Ovarian Neoplasms; Intestinal Neoplasms; Bone metastases; Rhabdomyosarcoma | Details |
Linsitinib | OSI-906; ASP-7487; OSI-906AA | Phase 3 Clinical | Astellas Pharma Inc, National Cancer Institute | Multiple Myeloma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Paraganglioma; Mouth Neoplasms; Lip Neoplasms; Eye Diseases; Orbital Diseases; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Exophthalmos; Carcinoma, Basosquamous; Prostatic Neoplasms; Sarcoma, Ewing; Breast Neoplasms; Adrenocortical Carcinoma; Liver Neoplasms; Graves Ophthalmopathy; Endocrine System Diseases; Hormone-Resistant Prostate Neoplasms; Skin Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Neoplasms; Hashimoto Disease; Head and Neck Neoplasms; Ovarian Neoplasms; Chondrosarcoma; Thyroid Diseases; Solid tumours; Carney Complex | Details |
FPI-1434 | [225Ac]-FPI-1434; FPX-01 | Phase 2 Clinical | Fusion Pharma | Solid tumours; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Neoplasms; Adrenocortical Carcinoma; Uveal melanoma; Breast Neoplasms; Endometrial Neoplasms; Uterine Cervical Neoplasms | Details |
Dalotuzumab | h7C-10; MK-0646; F-50-035 | Phase 2 Clinical | Pierre Fabre Group | Solid tumours; Rectal Neoplasms; Pancreatic Neoplasms; Neoplasms; Multiple Myeloma; Neuroendocrine Tumors; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung | Details |
CT-102 | CT-102 | Phase 2 Clinical | Hangzhou Tianlong Pharmaceutical Co Ltd, Institute Of Radiation And Radiation Medicine, Chinese Academy Of Military Medical Sciences | Liver Neoplasms; Carcinoma, Hepatocellular | Details |
Mecasermin Rinfabate | rhIGF-I/rhIGFBP-3; TAK-607; OHB-607; IGF-I/IGFBP-3; SHP-607; HGT-ROP-001 | Phase 2 Clinical | Insmed | Noonan Syndrome; Failure to Thrive; Cerebral Intraventricular Hemorrhage; Lung Diseases; Myotonic Dystrophy; Bronchopulmonary Dysplasia; Retinopathy of Prematurity; Laron Syndrome | Details |
Insulin growth factor receptor type 1 antisense therapy (Imvax) | IGV-001 | Phase 2 Clinical | Thomas Jefferson University | Glioblastoma | Details |
MHB018A | MHB 018A; MHB-018A | Phase 2 Clinical | Minghui Pharmaceutical (Hangzhou) Co Ltd | Graves Ophthalmopathy | Details |
PHP-1003 | PHP-1003; PHP1003 | Phase 2 Clinical | Suzhou Pulekang Pharmaceutical Technology Co Ltd | Graves Ophthalmopathy | Details |
Lonigutamab | VB-421 | Phase 2 Clinical | Pierre Fabre Group | Graves Ophthalmopathy | Details |
Cixutumumab | A-12; IMC-A12; LY-3012217; NSC-742460 | Phase 2 Clinical | Eli Lilly And Company | Chondrosarcoma, Extraskeletal Myxoid; Pinealoma; Brain Stem Neoplasms; Gliosarcoma; Breast Neoplasms; Gastrinoma; Medullary thyroid cancer (MTC); Lymphoma, Mantle-Cell; Neuroblastoma; Adenocarcinoma, Bronchiolo-Alveolar; Osteosarcoma; Retinoblastoma; Neurofibrosarcoma; Sarcoma; Sarcoma, Ewing; Prostatic Neoplasms; Glucagonoma; Mesothelioma; Glioma; Adenocarcinoma; Melanoma; Paraganglioma; Carcinoma, Non-Small-Cell Lung; Breast Neoplasms, Male; Carcinoma, Hepatocellular; Neuroectodermal Tumors, Primitive, Peripheral; Carcinoma, Neuroendocrine; Neuroendocrine Tumors; Esophageal Squamous Cell Carcinoma; Hemangiopericytoma; Esophageal adenocarcinoma; Sarcoma, Alveolar Soft Part; Lung Neoplasms; Rhabdomyosarcoma, Alveolar; Metastatic breast cancer; Colorectal Neoplasms; Hepatoblastoma; Stomach Neoplasms; Mesenchymoma; Rectal Neoplasms; Carcinoma, Merkel Cell; Esophageal Neoplasms; Insulinoma; Squamous Cell Carcinoma of Head and Neck; Rhabdomyosarcoma, Embryonal; Carcinoma; Desmoplastic Small Round Cell Tumor; Hema | Details |
Picropodophyllin | PPP; AXL-1717; NSC-36407 | Phase 2 Clinical | Axelar Ab | Astrocytoma; Carcinoma, Non-Small-Cell Lung | Details |
NNC0268-0965 | NNC0268-0965 | Phase 1 Clinical | Novo Nordisk A/S | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | Details |
IGF-1 receptor oligodeoxynucleotide-based immunotherapy (Thomas Jefferson University) | Phase 1 Clinical | Sidney Kimmel Cancer Center | Glioma | Details | |
Insulin-Like Growth Factor 1 (Wright State Physicians) | Phase 1 Clinical | Wright State Physicians | Nasolabial fold wrinkles; Healthy Aging; Burns; Sunburn | Details | |
SAR-446159 | ABL-301; SAR-446159 | Phase 1 Clinical | Abl Bio Inc | Parkinson Disease | Details |
VRDN-002 | VRDN-002 | Phase 1 Clinical | Viridian Therapeutics Inc | Graves Ophthalmopathy | Details |
LX-101 (Lirum Therapeutics) | 765IGF-MTX; IGF/MTX | Phase 1 Clinical | Lirum Therapeutics Inc | Head and Neck Neoplasms; Anemia, Refractory, with Excess of Blasts; Neoplasms; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Graves Ophthalmopathy; Brain Neoplasms; Breast Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Gastrointestinal Neoplasms; Melanoma | Details |
ZB-011 | ZB-011; ZB011 | Phase 1 Clinical | Viridian Therapeutics Inc | Graves Ophthalmopathy | Details |
Teprotumumab biosimilar(Boxiao Bio-pharma) | Phase 1 Clinical | Zhejiang Boxiao Bio-pharmaceutical Co Ltd | Graves Ophthalmopathy | Details | |
124I-CPD-1023-figitumumab | 124I-CPD-1028; 125I-CPD-1028; CPD-1028-[124I]; CPD-1028-[125I]; FPX-1028 | Phase 1 Clinical | Fusion Pharma | Neoplasms | Details |
ALTSuLIN | Clinical | Diabetes Mellitus, Type 1; Laron Syndrome | Details |
This web search service is supported by Google Inc.